Ronald Kirk Huntsman, Chief Executive Officer at Vivos Therapeutics, Inc. (VVOS), bought 14,000 shares at $0.53 ($7K) on 2023-06-20, disclosed to the SEC on 2023-06-20.
Open-market purchase of $7k VVOS by Chief Executive Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| VVOS | BUY | 2022-12-28 | $10K | — | Filing → |
| VVOS | BUY | 2022-06-03 | $24K | — | Filing → |
| VVOS | BUY | 2021-09-22 | $22K | — | Filing → |